Comparative Pharmacology
Head-to-head clinical analysis: GAMOPHEN versus PHISOHEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GAMOPHEN versus PHISOHEX.
GAMOPHEN vs PHISOHEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gamophen contains chlorhexidine gluconate, a cationic bisbiguanide that disrupts microbial cell membranes by binding to negatively charged phosphate groups on bacterial cell walls, leading to leakage of intracellular contents and cell death. It also inhibits bacterial enzymes and has broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and some viruses.
Disrupts bacterial cell wall synthesis by binding to the bacterial ribosome and inhibiting protein synthesis; also has surfactant properties that disrupt bacterial cell membrane integrity.
GAMOPHEN is not a recognized pharmaceutical drug. Please verify the drug name.
Apply topically as a 3% emulsion to affected area, rinse thoroughly; typically used 1-2 times daily for up to 10 days.
None Documented
None Documented
Terminal elimination half-life is 18-32 hours in adults, prolonged in renal impairment (up to 60 hours in severe cases).
Terminal elimination half-life approximately 6-7 hours in adults with normal renal function. Prolonged in renal impairment (up to 20 hours) due to reduced clearance of active metabolite (pentachlorophenol).
Primarily renal excretion of unchanged drug (50-70%) and glucuronide conjugates; biliary/fecal elimination accounts for <10%.
Renal (biliary/fecal negligible). Up to 10% of dose excreted unchanged in urine; remainder as metabolites (glucuronide and sulfate conjugates).
Category C
Category C
Antiseptic
Antiseptic